Quick Summary: Nucleic acid lateral flow tests and antigen rapid tests look identical to the end user — both produce a visible line on a strip in 1–15 minutes. Inside the cassette, however, they detect fundamentally different molecules. Antigen rapid tests detect pathogen proteins via antibody capture. Nucleic acid lateral flow tests detect amplified DNA or RNA, often after PCR, RAA, RPA, LAMP, or CRISPR Cas12/Cas13 cleavage. The trade-off is sensitivity vs cost vs equipment footprint. TiosBio’s LF-detect product family (JY0201, JY0301, JY0307, JY0308) supports the nucleic acid side of this comparison.
Two strips that look the same
Walk into any pharmacy in 2026 and you will find rapid antigen tests for COVID-19, influenza, RSV, strep, and more. The cassette format — a few drops of sample, a buffer, two visible lines after a few minutes — has become globally familiar. What is less visible is that the same lateral flow chromatographic format is also used for nucleic acid detection at the end of a molecular workflow. Distributors and procurement teams often need to explain the difference to clinicians, regulators, and customers. This article presents the comparison directly.
Side-by-side comparison
| Parameter | Antigen Rapid Test | Nucleic Acid Lateral Flow Test |
|---|---|---|
| What is detected | Pathogen protein (antigen) | Pathogen nucleic acid (DNA / RNA) |
| Detection chemistry | Antibody–antigen binding (sandwich / competitive) | Hybridization or label capture on amplified products |
| Sample-prep step | Buffer extraction (1–2 min) | Lysis + amplification (10–60 min) |
| Amplification step | Not required | PCR, RAA, RPA, LAMP, or CRISPR Cas12/13 |
| Total time to result | 5–30 min | 20–60 min including amplification |
| Analytical sensitivity | 10⁴–10⁶ copies/mL (typical LoD) | 10–10³ copies/mL (typical LoD) |
| Specificity | Antibody-dependent, cross-reactivity possible | Sequence-defined, very high |
| Equipment required | None | Heat block (isothermal) or thermocycler (PCR) |
| Multiplexing | 2–3 targets per strip (max) | 2–3 targets (e.g., JY0230 3-Plex) |
| Typical unit cost | $1–$5 USD | $3–$15 USD (strip + amplification) |
| Storage | 4–30 °C | 4–30 °C strips, –20 °C or RT for kits |
| Regulatory class (typical) | IVD Class II / B | IVD Class II–III / B–C |
Why nucleic acid LFA is gaining traction
Three trends are driving distributors to add nucleic acid lateral flow tests to portfolios that historically only carried antigen rapid tests:
- Sensitivity gap: Antigen rapid tests typically miss low-viral-load samples (e.g., early-infection or asymptomatic). Nucleic acid LFA paired with isothermal amplification routinely closes this gap by 2–4 orders of magnitude.
- Resistance and typing: Antibodies cannot easily distinguish bacterial drug-resistance variants or HPV subtypes. Sequence-based detection (CRISPR Cas12/13 strips, JY0301) handles this directly.
- Isothermal infrastructure: With RAA chemistry such as RPApex (JY0800/JY0808) at 39–42 °C, the equipment footprint is now close to antigen-test workflows — a heat block instead of a thermocycler.
When antigen rapid tests still win
- True point-of-care, no equipment: Pharmacies, schools, sports teams, home use.
- Cost-sensitive screening: Mass screening at $1–$2 per test.
- Symptomatic, high-viral-load patients: Antigen sensitivity is acceptable when viral load is high.
When nucleic acid LFA wins
- Early or low-load infections.
- Strain typing (HPV, influenza subtype, dengue serotype).
- Antimicrobial resistance markers (mecA, blaKPC, blaNDM, etc.).
- Asymptomatic surveillance.
- Veterinary and food-pathogen testing where antibody reagents are limited.
Hybrid portfolios
Most distributors in 2026 are not choosing between antigen and nucleic acid lateral flow tests — they are stocking both. The growth segment is nucleic acid LFA paired with isothermal amplification, which combines antigen-style operational simplicity with PCR-style analytical specificity. TiosBio supplies the nucleic acid LFA layer (JY0201 universal, JY0230 3-Plex, JY0301 Cas12/13) and the isothermal amplification layer (RPApex JY0800/JY0808) needed to build this hybrid line.
Frequently Asked Questions
Are nucleic acid lateral flow tests considered “molecular tests”?
Yes. Even though the readout is a visual strip, the detected analyte is amplified DNA or RNA, so the workflow is classified as a molecular diagnostic. This includes RAA-LFA, LAMP-LFA, and CRISPR-LFA workflows.
Can a single cassette do both antigen and nucleic acid detection?
Not in a single integrated cassette today. The chemistry is fundamentally different. Most workflows run them as separate tests — antigen for first-line screening, nucleic acid for confirmation or asymptomatic detection.
How sensitive are nucleic acid LFA strips compared to qPCR?
With pre-amplification (RAA, LAMP, PCR), nucleic acid LFA can approach qPCR sensitivity, typically 10–10³ copies/mL depending on the target and chemistry. Without amplification, sensitivity drops 3–4 orders of magnitude.
Are nucleic acid lateral flow tests CE-IVD or FDA-cleared?
Several products in the market are CE-IVD or FDA-cleared. TiosBio’s catalogue products are research-use components; OEM/ODM customers register under their own regulatory pathway in the destination market.
Conclusion
Antigen rapid tests and nucleic acid lateral flow tests share the same end-user format but solve different problems. Antigen tests win on cost and equipment footprint. Nucleic acid lateral flow tests win on sensitivity, specificity, and applicability to typing and resistance markers. Distributors building a 2026 POCT portfolio should stock both, with nucleic acid lateral flow as the growth axis. Contact us for product specifications, OEM/ODM discussion, and technical documentation.